Endo, Penwest to block Actavis plan for Opana ingredient

02/18/2008 | American City Business Journals

Endo Pharmaceuticals Holdings and Penwest Pharmaceuticals Co. have declared they will "pursue all available legal and regulatory avenues" to defend patents for their Opana ER pain drug after Actavis South Atlantic said it is seeking FDA approval for extended-release tablets with Opana's active ingredient. Endo and Penwest say Opana is protected until June 22, 2009.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN